Immutep Ltd (AU:IMM)
ASX:IMM
Want to see AU:IMM full AI Analyst Report?
Top Page
Immutep Ltd
(Sydney:IMM)
Select Model
Select Model
Rating:42Neutral
Price Target:
AU$0.05
▼(-27.14% Downside)
Action:Reiterated
Date:04/22/26
The score is held down primarily by weak financial performance driven by persistent losses and negative cash flows, despite a relatively conservative balance sheet. Technicals also remain unfavorable with price below key moving averages and a negative MACD. Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Platform & Pipeline
A proprietary LAG-3 platform with multiple clinical-stage candidates (efti, leramilimab and others) is a durable competitive asset in immuno-oncology. A diversified pipeline reduces single-asset binary risk, enables multiple value-inflection points and supports partner interest over years.
Negative Factors
Persistent Losses
Sustained negative margins across gross, operating and net lines indicate the company cannot yet generate product economics. This structural unprofitability limits the ability to self-fund development, raises dependence on external capital and increases dilution risk over multiple funding rounds.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform & Pipeline
A proprietary LAG-3 platform with multiple clinical-stage candidates (efti, leramilimab and others) is a durable competitive asset in immuno-oncology. A diversified pipeline reduces single-asset binary risk, enables multiple value-inflection points and supports partner interest over years.
Read all positive factors
Immutep Ltd (IMM) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$78.11M
Dividend YieldN/A
Average Volume (3M)4.11M
Price to Earnings (P/E)―
Beta (1Y)2.35
Revenue GrowthN/A
EPS Growth-73.11%
CountryAU
Employees19
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,473,721,300
10 Day Avg. Volume7,757,821
30 Day Avg. Volume4,106,545
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)2.43
Price to Sales (P/S)69.27
P/FCF Ratio-5.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.17Price Target Upside142.86% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.05
Revenue Forecast (FY)AU$26.73M
Immutep Ltd Business Overview & Revenue Model
Company Description
Immutep Limited, a biotechnology company, engages in the research and development of pharmaceutical products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its lead product candidate is eftila...
How the Company Makes Money
Immutep is a pre-commercial, clinical-stage biotech and does not primarily generate revenue from product sales. Its cash inflows have historically been driven by (1) collaboration and licensing arrangements—where partners may fund or share develop...
Immutep Ltd Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.98M | 5.04M | 3.84M | 3.51M | 170.37K | 3.86M |
| Gross Profit | -31.23M | -56.37M | -37.70M | 1.44M | -1.89M | 1.79M |
| EBITDA | -83.33M | -62.88M | -44.54M | -42.88M | -31.87M | -20.72M |
| Net Income | -83.92M | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
Balance Sheet | ||||||
| Total Assets | 147.20M | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 99.13M | 129.69M | 181.88M | 123.42M | 80.00M | 60.13M |
| Total Debt | 2.16M | 1.63M | 1.59M | 1.23M | 1.73M | 2.82M |
| Total Liabilities | 48.30M | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Stockholders Equity | 98.90M | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
Cash Flow | ||||||
| Free Cash Flow | -62.28M | -62.10M | -35.75M | -35.93M | -30.25M | -17.66M |
| Operating Cash Flow | -62.15M | -62.05M | -34.82M | -35.88M | -30.23M | -17.64M |
| Investing Cash Flow | 59.60M | -38.53M | -21.02M | -31.00K | -22.91K | -15.60K |
| Financing Cash Flow | -210.50K | -525.12K | 95.18M | 76.04M | 50.33M | 52.68M |
Immutep Ltd Technical Analysis
Negative
0.07
Price Trends
0.06
Negative
0.22
Negative
0.25
Negative
Market Momentum
>-0.01
Negative
33.62
Neutral
17.40
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:IMM, the sentiment is Negative. The current price of 0.07 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.06, and below the 200-day MA of 0.25, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 33.62 is Neutral, neither overbought nor oversold. The STOCH value of 17.40 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:IMM.
Immutep Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
60 Neutral | AU$4.42B | -406.54 | -2.08% | ― | 59.13% | -121.52% | |
55 Neutral | AU$70.88M | -1.58 | -93.08% | ― | 116.02% | 75.56% | |
52 Neutral | AU$2.77B | -25.03 | -14.02% | ― | 1069.25% | 18.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$294.65M | -90.75 | -15.96% | ― | 364.97% | 74.50% | |
44 Neutral | AU$47.82M | -0.57 | -134.65% | ― | ― | 62.72% | |
42 Neutral | AU$78.11M | -0.93 | -69.20% | ― | ― | -73.11% |
* Healthcare Sector Average
AU:IMM
Immutep Ltd
0.05
-0.23
-81.07%
AU:IMU
Imugene
0.12
-0.40
-77.45%
AU:MSB
Mesoblast Limited
2.14
0.55
34.17%
AU:SPL
Starpharma Holdings Limited
0.70
0.61
660.87%
AU:TLX
Telix Pharmaceuticals
13.03
-13.02
-49.98%
AU:RAD
Radiopharm Theranostics Limited
0.02
>-0.01
-28.57%
Immutep Ltd Corporate Events
Immutep Links Eftilagimod Immune Activation to Longer Survival in Late-Stage Cancer
May 27, 2026
Immutep reported a pooled analysis of five clinical trials showing that late-stage cancer patients receiving 30 mg subcutaneous eftilagimod alfa plus standard-of-care therapies had significantly increased absolute lymphocyte counts and a median ov...
JPMorgan Entities Exit Substantial Holder Status in Immutep
May 10, 2026
JPMorgan Chase Co. and its affiliates have notified Immutep Ltd that they have ceased to be a substantial shareholder in the company as of 6 May 2026. The change follows a series of securities lending, rehypothecation, and proprietary trading tra...
Immutep Faces Nasdaq Bid-Price Deficiency but Retains Listings as It Seeks Compliance
Apr 30, 2026
Immutep Limited has received a notice from Nasdaq that its American Depositary Shares no longer meet the exchange’s minimum bid price requirement of US$1.00 per share, after trading below that threshold for 30 consecutive business days throu...
Immutep Halts Key Lung Cancer Trial but Pipeline Advances on Solid Cash Base
Apr 30, 2026
Immutep has discontinued its pivotal TACTI-004 Phase III trial in first-line non-small cell lung cancer after an interim futility analysis showed the eftilagimod alfa combination arm underperformed the control arm, prompting an orderly wind-down a...
Immutep to Present New Eftilagimod Alfa Data at ASCO 2026
Apr 22, 2026
Immutep announced that an abstract on its lead candidate eftilagimod alfa has been accepted for poster presentation at the 2026 American Society of Clinical Oncology Annual Meeting in Chicago. The study will be presented in the Developmental Thera...
Immutep Ends Key Lung Cancer Trial but Stresses Strength of Pipeline
Apr 8, 2026
Immutep has discontinued its multinational, randomized, double-blind Phase III TACTI-004 study in first-line non-small cell lung cancer after a pre-specified interim futility analysis showed the trial was unlikely to meet its endpoints. Management...
Insignia Financial Ceases to Be Substantial Holder in Immutep
Mar 19, 2026
Insignia Financial Ltd, acting on behalf of itself and its subsidiaries, has notified Immutep Ltd that it has ceased to be a substantial holder in the company as of 13 March 2026. The change follows a series of on-market share purchases and sales ...
Immutep Reports Positive Phase I Progress for First-in-Class Autoimmune Drug IMP761
Mar 18, 2026
Immutep reported positive progress from its first-in-human Phase I trial of IMP761, a first-in-class LAG-3 agonist antibody designed to suppress pathogenic T cell responses in autoimmune diseases. The single ascending dose part of the study has be...
UBS Group Ceases to Be Substantial Shareholder in Immutep
Mar 18, 2026
UBS Group AG and its related entities have notified Immutep Ltd that they have ceased to be a substantial shareholder in the company as of 16 March 2026, following changes in their relevant interests in Immutep’s voting securities. The chang...
Immutep Trading Resumes on ASX After Key Phase III Trial Update
Mar 12, 2026
Immutep Limited has had the suspension of trading in its securities on the ASX lifted, following the release of an announcement regarding its TACTI-004 (KEYNOTE-F91) Phase III trial. The trial is evaluating the company’s lead candidate, efti...
Immutep Halts Pivotal Lung Cancer Trial After Futility Review
Mar 12, 2026
Immutep has halted its Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small cell lung cancer after an Independent Data Monitoring Committee recommended discontinuation for futility based on an interim analysis of safety and effica...
Immutep Shares Suspended Pending Key Phase III Trial Futility Update
Mar 10, 2026
Immutep Limited has requested and received a voluntary suspension of trading in its ordinary shares on the ASX, following an earlier trading halt, while it prepares an announcement on the interim futility analysis of its Phase III TACTI-004 (KEYNO...
Immutep Halts Trading Ahead of Key Phase III Trial Futility Analysis
Mar 6, 2026
Immutep Limited has requested and been granted a trading halt on its ordinary shares on the ASX, effective 6 March 2026, pending the release of an announcement. The halt is intended to prevent trading on an uninformed basis while the company prepa...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.